Eiger BioPharmaceuticals, Inc. Quarterly Revenues in USD from Q1 2021 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Eiger BioPharmaceuticals, Inc. annual/quarterly Revenues history and growth rate from Q1 2021 to Q3 2023.
  • Eiger BioPharmaceuticals, Inc. Revenues for the quarter ending September 30, 2023 was $3.21M, a 20.3% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Revenues for 2023 was $15.8M, a 17% increase from 2022.
  • Eiger BioPharmaceuticals, Inc. annual Revenues for 2022 was $13.5M, a 11.1% increase from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Revenues for 2021 was $12.1M.
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $3.21M -$815K -20.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $4.64M +$552K +13.5% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q4 2022 $13.5M $2.7M -$664K -19.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-08
Q3 2022 $14.1M $4.02M +$985K +32.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $13.2M $4.09M +$1.99M +95.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $11.2M $2.67M -$973K -26.7% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $12.1M $3.36M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 $3.04M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $2.1M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $3.65M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.